EPCAM and breast carcinoma: This system is the only device to have been approved by the US Food and Drug Administration (FDA) for clinical application in prostate, colorectal, and breast cancers (Parsortix®, ANGLE, United Kingdom and Toronto, Canada, has also recently been approved), and consists of epithelial cell adhesion molecule (EpCAM) antibodies linked to magnetic beads [20].